FOR decades, chemotherapy against lymphoma was conducted by CHOP (cyclophosphamide, hydroxidoxorubicin, vincristine, prednisone). In a further development of drugs created a more powerful way to eradicate the lymphoma. One is rituximab.
In contrast to CHOP, rituximab is a drug produced by the monoclonal antibody technology. Technology makes rituximab were able to track and destroy cancer cells specifically.
More than 85% of lymphomas derived from B-cells. Rituximab works by binding to a protein that is CD20 + were found in 95% of the surface of B cells (a type of lymphocyte cell) malignant. Furthermore, the body's natural defenses will be recruited to attack and kill B-cells. Once the malignant cells are destroyed, then will be replaced with normal B-cells. Thus, the body's defense system will be regenerated by normal B-cells.
Read more »
